Compare NBTX & BGSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTX | BGSI |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | France | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2018 | 2025 |
| Metric | NBTX | BGSI |
|---|---|---|
| Price | $39.35 | $90.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $36.00 | ★ $157.00 |
| AVG Volume (30 Days) | ★ 153.6K | 36.9K |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 0.38% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.17 | $35.07 |
| Revenue Next Year | N/A | $8.01 |
| P/E Ratio | ★ N/A | $231.07 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.41 | $82.26 |
| 52 Week High | $57.14 | $183.10 |
| Indicator | NBTX | BGSI |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 46.54 |
| Support Level | $36.98 | $88.97 |
| Resistance Level | $41.06 | $99.16 |
| Average True Range (ATR) | 2.95 | 3.44 |
| MACD | -0.29 | -0.13 |
| Stochastic Oscillator | 15.87 | 50.37 |
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. The Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.